Get started
Author

Florence Geiguer

Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine
2017 · Françoise Descotes, Norelyakin Kara, et al. · British Journal of Cancer · 96
Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR Biorad detection assay, BEAMing assay, and NGS strategy)
2018 · Jessica Garcia, Julien Forestier, et al. · Oncotarget · 62
PDF
Sensitivity, specificity, and accuracy of a liquid biopsy approach utilizing molecular amplification pools
2021 · Jessica Garcia, Nick Kamps-Hughes, et al. · Scientific Reports · 46
PDF
Embryonated Chicken Tumor Xenografts Derived from Circulating Tumor Cells as a Relevant Model to Study Metastatic Dissemination: A Proof of Concept
2022 · Xavier Rousset, Denis Maillet, et al. · Cancers · 21
PDF
Profiling of circulating tumor DNA in plasma of non‐small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells
2019 · Jessica Garcia, Anne‐Sophie Wozny, et al. · Cancer Medicine · 21
PDF
Routine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAMTM EGFR V2 and NGS Technologies
2021 · Jessica Garcia, Arnaud Gauthier, et al. · Molecular Diagnosis & Therapy · 10
PDF
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
2019 · Jessica Garcia, David Barthelemy, et al. · Journal of Visualized Experiments · 9
Circulating H3K27 Methylated Nucleosome Plasma Concentration: Synergistic Information with Circulating Tumor DNA Molecular Profiling
2023 · Emmanuel Grolleau, Julie Candiracci, et al. · Biomolecules · 8
PDF
Paired Comparison of Routine Molecular Screening of Patient Samples with Advanced Non-Small Cell Lung Cancer in Circulating Cell-Free DNA Using Three Targeted Assays
2023 · David Barthelemy, Gaelle Lescuyer, et al. · Cancers · 7
PDF
Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon‐19‐deleted advanced NSCLC mutation
2025 · David Barthélémy, Arnaud Vigneron, et al. · FEBS Open Bio · 5
PDF
Whole transcriptomics analyses of mimicking circulating tumor cells (CTCs) by single-cell RNA sequencing (scRNAseq)
2019 · J. Garcia, F. Monjaret, et al. · Annals of Oncology · 4
Author response for "Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon‐19‐deleted advanced NSCLC mutation"
2024 · David Barthélémy, Arnaud Vigneron, et al. · Publons reviews and discussion
Abstract 4866: Pharmacological mechanisms of osimertinib in advanced non-small lung cancer bearing the deletion exon 19 of EGFR In an original chicken chorioallantoic membrane (CAM) Model
2023 · David Barthelemy, Arnaud Vigneron, et al. · Cancer Research
Abstract 2163: Circulating H3K27 nucleosomes to monitor lung cancer patients during treatment, a universal biomarker quantifying the molecular residual disease (MRD) in plasma samples
2023 · Emmanuel Grolleau, Julie Candiracci, et al. · Cancer Research
Abstract 6691: Paired comparison of routine molecular screening of patient samples with advanced non-small cell lung cancer in circulating cell-free DNA using OncoBEAMTM EGFR V2, targeted next-generation sequencing Plasma-SeqSensei™ Solid Cancer IVD Kit and custom-validated NGS assay
2023 · David Barthelemy, Emmanuel Grolleau, et al. · Cancer Research
Non invasive prediction of recurrences in bladder cancer by detecting TERT promoter mutations in urine
2017 · N. Kara, F. Descotes, et al. · European Urology Supplements
Works count: 16
Citation count: 289
H-index: 8
I10-index: 6
Year
Topic
Type